אוזמפיק, שאושרה ב-2017 כתרופה לסוכרת, החלה לצבור יחסי ציבור כתרופה אשר מועילה גם נגד השמנה בתחילת שנות ה-2020. נובו הגישה את ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in individuals aged 12 ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 ...

מחקר ישראלי חדש מסורוקה מצא כי זריקות מהדור החדש לטיפול בסוכרת והשמנת יתר עשויות לשפר את מצבם של חולות הסובלות מלחץ ...

The companies will sell the drug at a reduced price of $499 a month. Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option.

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

Novo Nordisk sparked the obesity drug revolution with Ozempic and Wegovy. Now it’s racing to avoid falling further behind Eli Lilly. On Monday, Novo announced new partnerships with telehealth ...